| Identification | Back Directory | [Name]
7-((benzo[d]thiazol-2-ylamino)(4-(difluoromethoxy)phenyl)methyl)quinolin-8-ol | [CAS]
446826-86-4 | [Synonyms]
KIN-1400
KIN-1400
(KIN1400
KIN1400 >=98% (HPLC)
7-[(2-benzothiazolylamino)[4-(difluoromethoxy)phenyl]methyl]-8-quinolinol
8-Quinolinol, 7-[(2-benzothiazolylamino)[4-(difluoromethoxy)phenyl]methyl]-
7-((benzo[d]thiazol-2-ylamino)(4-(difluoromethoxy)phenyl)methyl)quinolin-8-ol
7-[(1,3-benzothiazol-2-ylamino)-[4-(difluoromethoxy)phenyl]methyl]quinolin-8-ol | [Molecular Formula]
C24H17F2N3O2S | [MDL Number]
MFCD02655498 | [MOL File]
446826-86-4.mol | [Molecular Weight]
449.47 |
| Chemical Properties | Back Directory | [Boiling point ]
651.1±65.0 °C(Predicted) | [density ]
1.443±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO:30.0(Max Conc. mg/mL);66.74(Max Conc. mM)
DMSO:PBS (pH 7.2) (1:2):0.3(Max Conc. mg/mL);0.67(Max Conc. mM)
Ethanol:2.0(Max Conc. mg/mL);4.45(Max Conc. mM)
DMF:30.0(Max Conc. mg/mL);66.74(Max Conc. mM) | [form ]
powder | [pka]
4.23±0.50(Predicted) | [color ]
white to beige | [InChI]
1S/C24H17F2N3O2S/c25-23(26)31-16-10-7-15(8-11-16)20(29-24-28-18-5-1-2-6-19(18)32-24)17-12-9-14-4-3-13-27-21(14)22(17)30/h1-13,20,23,30H,(H,28,29) | [InChIKey]
YDSHHDISKUSKFW-UHFFFAOYSA-N | [SMILES]
OC(C(N=CC=C1)=C1C=C2)=C2C(C3=CC=C(OC(F)F)C=C3)NC4=NC5=CC=CC=C5S4 |
| Hazard Information | Back Directory | [Uses]
KIN1400 is a potent IRF3 activator. KIN1400 triggers IRF3-dependent innate immune antiviral genes (RIG-I, MDA5, IFIT1, and Mx1) and IFN-β expression. KIN1400 inhibits WNV and DV, two mosquito-borne members of the Flaviviridae and the genus Flavivirus. KIN1400 also inhibits HCV replication. KIN1400 induces innate antiviral immunity through a MAVS-IRF3 axis[1]. | [Biological Activity]
KIN1400 is innate immune agonists of IRF3 activation th at induces IRF3 and MAVS dependent innate immune antiviral genes and IFNβ expression. KIN1400 is a broad spectrum antiviral compound th at suppresses replication of hepatitis C virusWest Nile virusdengue virus and other Flaviviridaeas well as Filoviridae (EV)Orthomyxoviridae (influenza A virus)Arenaviridae (LV) and Paramyxoviridae (RCVNV). | [References]
[1] Pattabhi S, et al. Targeting Innate Immunity for Antiviral Therapy through Small Molecule Agonists of the RLR Pathway. J Virol. 2015 Dec 16;90(5):2372-87. DOI:10.1128/JVI.02202-15 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|